Mortalidade por leishmaniose visceral: aspectos clínicos e laboratoriais

Oliveira, Janaina Michelle de; Fernandes, Ana Claudia; Dorval, Maria Elizabeth Cavalheiros; Alves, Túlia Peixoto; Fernandes, Thiago Dias; Oshiro, Elisa Teruya; Oliveira, Ana Lúcia Lyrio de.
Rev. Soc. Bras. Med. Trop ; 43(2): 188-193, Mar.-Apr. 2010. tab
Artigo em Português | LILACS | ID: lil-545785

Documentos relacionados

  1. In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes.
  2. Reversible dilated cardiomyopathy associated with amphotericin B therapy.
  3. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
  4. In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis.
  5. Stigmasterol as a potential biomarker for amphotericin B resistance in Leishmania donovani.
  6. Visceral leishmaniasis after orthotopic liver transplantation: a rare cause of infection.
  7. Evaluating drug resistance in visceral leishmaniasis: the challenges.
  8. Exploring Novel Drug Combinations: The Therapeutic Potential of Selanyl Derivatives for Leishmania Treatment.
  9. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
  10. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.